Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients

the SafeHer Study Group

نتاج البحث: المساهمة في مجلةArticleمراجعة النظراء

39 اقتباسات (Scopus)

بصمة

أدرس بدقة موضوعات البحث “Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients'. فهما يشكلان معًا بصمة فريدة.

Agricultural and Biological Sciences

Pharmacology, Toxicology and Pharmaceutical Science

Medicine and Dentistry